Sunday, June 24, 2018

NPR Profiles Vijay Prasad, Oncologist Who Critiques "Hype"

In September 2016, almost two years ago, I a column about then-current articles under the category of "precision medicine sceptics."

On Sunday, June 24, NPR runs a seven minute interview and an on-line article about Vijay Prasad, the OHSU-based oncologist who is a prolific author of articles "calling out hype" in the field of precision medicine.   The NPR article is here.   See also what looks like an open-access article at the trade journal Cancer Letter, dated June 22, here.

Prasad was part of a "debate" at the June Chicago ASCO on precision medicine, as covered by NPR.   Just in April, see coverage of a "debate" on the same topic at AACR, here.



 Another West Coast academic, Stanford's John Ioannadis, is equally prolific in hype-bashing productivity; e.g. recent blog article here.

I'll let you assess the NPR interview for yourself.  If of interest, I've clipped a couple dozen of Prasad's 2017-2018 articles from PubMed below the break.




   

1.
Clinical trials involving positron emission tomography and prostate cancer: an analysis of the ClinicalTrials.gov database.
Cihoric N, Vlaskou Badra E, Tsikkinis A, Prasad V, Kroeze S, Igrutinovic I, Jeremic B, Beck M, Zschaeck S, Wust P, Ghadjar P.
Radiat Oncol. 2018 Jun 18;13(1):113. doi: 10.1186/s13014-018-1057-3.
PMID:
 
29914515
 
Free Article
Similar articles Remove from clipboard
2.
The need to assess financial adverse events.
Nastoupil LJ, Prasad V, Flowers CR.
Lancet Haematol. 2018 Jun 12. pii: S2352-3026(18)30072-3. doi: 10.1016/S2352-3026(18)30072-3. [Epub ahead of print] No abstract available.
PMID:
 
29907551
Similar articles Remove from clipboard
3.
If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis.
Deloughery EP, Prasad V.
J Gen Intern Med. 2018 Jun 4. doi: 10.1007/s11606-018-4498-3. [Epub ahead of print] No abstract available.
PMID:
 
29869138
Similar articles Remove from clipboard
4.
Cost-effectiveness of Nusinersen for Spinal Muscular Atrophy-Reply.
Prasad V.
JAMA Pediatr. 2018 May 7. doi: 10.1001/jamapediatrics.2018.0733. [Epub ahead of print] No abstract available.
PMID:
 
29800980
Similar articles Remove from clipboard
5.
Direct-to-Consumer Genetic Testing: The Implications of the US FDA's First Marketing Authorization for BRCA Mutation Testing.
Gill J, Obley AJ, Prasad V.
JAMA. 2018 Jun 19;319(23):2377-2378. doi: 10.1001/jama.2018.5330. No abstract available.
PMID:
 
29800087
Similar articles Remove from clipboard
6.
Low-value approvals and high prices might incentivize ineffective drug development.
Prasad V, McCabe C, Mailankody S.
Nat Rev Clin Oncol. 2018 May 14. doi: 10.1038/s41571-018-0030-2. [Epub ahead of print] No abstract available.
PMID:
 
29760505
Similar articles Remove from clipboard
7.
Concerns About the Approval of Nusinersen Sodium by the US Food and Drug Administration.
Gerrity MS, Prasad V, Obley AJ.
JAMA Intern Med. 2018 Jun 1;178(6):743-744. doi: 10.1001/jamainternmed.2018.0869. No abstract available.
PMID:
 
29710299
Similar articles Remove from clipboard
8.
Estimation of The Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology.
Marquart J, Chen EY, Prasad V.
JAMA Oncol. 2018 Apr 17. doi: 10.1001/jamaoncol.2018.1660. [Epub ahead of print]
PMID:
 
29710180
Similar articles Remove from clipboard
9.
Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy.
Hernandez I, Prasad V, Gellad WF.
JAMA Oncol. 2018 Apr 26. doi: 10.1001/jamaoncol.2018.0977. [Epub ahead of print] No abstract available.
PMID:
 
29710129
Similar articles Remove from clipboard
10.
When is crossover desirable in cancer drug trials and when is it problematic?
Haslam A, Prasad V.
Ann Oncol. 2018 May 1;29(5):1079-1081. doi: 10.1093/annonc/mdy116. No abstract available.
PMID:
 
29648572
 
Free PMC Article
Similar articles Remove from clipboard
11.
Assessing Pharmaceutical Research and Development Costs-Reply.
Prasad V, Mailankody S.
JAMA Intern Med. 2018 Apr 1;178(4):588-589. doi: 10.1001/jamainternmed.2017.8737. No abstract available.
PMID:
 
29610885
Similar articles Remove from clipboard
12.
Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings.
Hayes MJ, Prasad V.
Hastings Cent Rep. 2018 Mar;48(2):10-13. doi: 10.1002/hast.833.
PMID:
 
29590518
Similar articles Remove from clipboard
13.
Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study.
Wagner J, Marquart J, Ruby J, Lammers A, Mailankody S, Kaestner V, Prasad V.
BMJ. 2018 Mar 7;360:k668. doi: 10.1136/bmj.k668.
PMID:
 
29514787
 
Free PMC Article
Similar articles Remove from clipboard
14.
Is "Precision Medicine" Ready to Use in Primary Care Practice? No: It Is Barely Ready for Testing.
Prasad V, Obley A.
Am Fam Physician. 2017 Dec 15;96(12):769-770. No abstract available.
PMID:
 
29431373
Similar articles Remove from clipboard
15.
Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes.
Hayes MJ, Kaestner V, Mailankody S, Prasad V.
CMAJ Open. 2018 Jan 15;6(1):E31-E38. doi: 10.9778/cmajo.20170088.
PMID:
 
29343497
 
Free PMC Article
Similar articles Remove from clipboard
16.
Cancer Drugs Approved Based on Biomarkers and Not Tumor Type-FDA Approval of Pembrolizumab for Mismatch Repair-Deficient Solid Cancers.
Prasad V, Kaestner V, Mailankody S.
JAMA Oncol. 2018 Feb 1;4(2):157-158. doi: 10.1001/jamaoncol.2017.4182. No abstract available.
PMID:
 
29285544
Similar articles Remove from clipboard
17.
Crossover is not associated with faster trial accrual.
Chen EY, Prasad V.
Ann Oncol. 2018 Mar 1;29(3):776-777. doi: 10.1093/annonc/mdx793. No abstract available.
PMID:
 
29267893
Similar articles Remove from clipboard
18.
Why the US Centers for Medicare and Medicaid Services (CMS) should have required a randomized trial of Foundation Medicine (F1CDx) before paying for it.
Prasad V.
Ann Oncol. 2018 Feb 1;29(2):298-300. doi: 10.1093/annonc/mdx786. No abstract available.
PMID:
 
29236937
Similar articles Remove from clipboard
19.
Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals.
Lammers A, Wang R, Cetnar J, Prasad V.
Blood Cancer J. 2017 Nov 30;7(12):637. doi: 10.1038/s41408-017-0008-9. No abstract available.
PMID:
 
29187747
 
Free PMC Article
Similar articles Remove from clipboard
20.
Me too-drugs with limited benefits - the tale of regorafenib for HCC.
Gyawali B, Prasad V.
Nat Rev Clin Oncol. 2018 Jan;15(1):62. doi: 10.1038/nrclinonc.2017.190. Epub 2017 Nov 28.
PMID:
 
29182165
Similar articles Remove from clipboard
21.
Overall Survival vs Disease-Specific Survival-Reply.
Mailankody S, Prasad V.
JAMA Oncol. 2018 Apr 1;4(4):586-587. doi: 10.1001/jamaoncol.2017.3865. No abstract available.
PMID:
 
29167883
Similar articles Remove from clipboard
22.
Financial conflicts of interest among editorialists in high-impact journals.
Kaestner V, Prasad V.
Blood Cancer J. 2017 Sep 15;7(9):e611. doi: 10.1038/bcj.2017.92. No abstract available.
PMID:
 
29016572
 
Free PMC Article
Similar articles Remove from clipboard
23.
Job postings for biopharmaceutical industry in medical journals is 45-fold greater for hematology oncology than medical specialties.
Kaestner V, Prasad V.
Blood Cancer J. 2017 Sep 15;7(9):e609. doi: 10.1038/bcj.2017.91. No abstract available. Erratum in: Blood Cancer J. 2017 Nov 3;7(11):e619.
PMID:
 
29016568
 
Free PMC Article
Similar articles Remove from clipboard
24.
Reversal of warfarin era thinking.
Shatzel JJ, Daughety MM, Prasad V, DeLoughery TG.
J Intern Med. 2018 Apr;283(4):408-410. doi: 10.1111/joim.12697. Epub 2017 Oct 17. No abstract available.
PMID:
 
28981174
Similar articles Remove from clipboard
25.
Non-Inferiority Trials in Medicine: Practice Changing or a Self-Fulfilling Prophecy?
Prasad V.
J Gen Intern Med. 2018 Jan;33(1):3-5. doi: 10.1007/s11606-017-4191-y. No abstract available.
PMID:
 
28980180
Similar articles Remove from clipboard
26.
Do cancer drugs improve survival or quality of life?
Prasad V.
BMJ. 2017 Oct 4;359:j4528. doi: 10.1136/bmj.j4528. No abstract available.
PMID:
 
28978548
 
Free PMC Article
Similar articles Remove from clipboard
27.
Immunotherapy: Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers.
Prasad V.
Nat Rev Clin Oncol. 2018 Jan;15(1):11-12. doi: 10.1038/nrclinonc.2017.156. Epub 2017 Oct 4. No abstract available.
PMID:
 
28975930
Similar articles Remove from clipboard
28.
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval.
Prasad V, Mailankody S.
JAMA Intern Med. 2017 Nov 1;177(11):1569-1575. doi: 10.1001/jamainternmed.2017.3601.
PMID:
 
28892524
Similar articles Remove from clipboard
29.
Conflicts of interest in Twitter.
Kaestner V, Brown A, Tao D, Prasad V.
Lancet Haematol. 2017 Sep;4(9):e408-e409. doi: 10.1016/S2352-3026(17)30109-6. No abstract available.
PMID:
 
28863800
Similar articles Remove from clipboard
30.
A further strategy to combat the high price of anticancer drugs.
Prasad V, De Jesús K, Mailankody S.
Nat Rev Clin Oncol. 2017 Oct;14(10):629. doi: 10.1038/nrclinonc.2017.137. Epub 2017 Aug 22. No abstract available.
PMID:
 
28829055
Similar articles Remove from clipboard
31.
Is "Do Everything!" Always Appropriate?-Reply.
Beer TM, Prasad V.
JAMA Oncol. 2017 Nov 1;3(11):1588-1589. doi: 10.1001/jamaoncol.2017.2349. No abstract available.
PMID:
 
28817761
Similar articles Remove from clipboard
32.
Pemetrexed in Nonsquamous Non-Small-Cell Lung Cancer: The Billion Dollar Subgroup Analysis.
Gyawali B, Prasad V.
JAMA Oncol. 2018 Jan 1;4(1):17-18. doi: 10.1001/jamaoncol.2017.1944. No abstract available.
PMID:
 
28750129
Similar articles Remove from clipboard
33.
Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
Kemp R, Prasad V.
BMC Med. 2017 Jul 21;15(1):134. doi: 10.1186/s12916-017-0902-9.
PMID:
 
28728605
 
Free PMC Article
Similar articles Remove from clipboard